DiscoverPharmaceutical ExecutiveRecent Licensing Agreement Poised to Advance Company ADC
Recent Licensing Agreement Poised to Advance Company ADC

Recent Licensing Agreement Poised to Advance Company ADC

Update: 2024-01-26
Share

Description

Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.
Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Recent Licensing Agreement Poised to Advance Company ADC

Recent Licensing Agreement Poised to Advance Company ADC

Pharmaceutical Executive Podcast